**Index**

<table>
<thead>
<tr>
<th>Term</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>adjacent innovation</td>
<td>xvii</td>
</tr>
<tr>
<td>Adriaans, Huib</td>
<td>54, 55, 56, 59, 61, 62–3, 65</td>
</tr>
<tr>
<td>advertising</td>
<td>57–8, 63, 97, 98, 100, 106, 111, 115, 116</td>
</tr>
<tr>
<td>AkzoNobel 22–4</td>
<td></td>
</tr>
<tr>
<td>new venture team composition</td>
<td>37–8</td>
</tr>
<tr>
<td>new venture team relationship</td>
<td>40</td>
</tr>
<tr>
<td>new venturing model</td>
<td>31–2</td>
</tr>
<tr>
<td>new venturing plans</td>
<td>29–32</td>
</tr>
<tr>
<td>new venturing portfolio</td>
<td>35–6</td>
</tr>
<tr>
<td>AkzoNobel New Ventures 120</td>
<td></td>
</tr>
<tr>
<td>demise 28–9</td>
<td></td>
</tr>
<tr>
<td>formation 24–6</td>
<td></td>
</tr>
<tr>
<td>model 31, 33, 122</td>
<td></td>
</tr>
<tr>
<td>parent company relationship</td>
<td>32, 38–40, 127, 128</td>
</tr>
<tr>
<td>portfolio 32, 34–5, 125</td>
<td></td>
</tr>
<tr>
<td>revenue projections</td>
<td>30</td>
</tr>
<tr>
<td>structure 24</td>
<td></td>
</tr>
<tr>
<td>team composition 36–7, 126</td>
<td></td>
</tr>
<tr>
<td>'arm's length' innovation</td>
<td>38, 127, 130</td>
</tr>
<tr>
<td>Armstrong, Graeme</td>
<td>23</td>
</tr>
<tr>
<td>BAC BV 43–6</td>
<td></td>
</tr>
<tr>
<td>from spin-out to exit</td>
<td>46–8</td>
</tr>
<tr>
<td>structure 45</td>
<td></td>
</tr>
<tr>
<td>Bens, Wim</td>
<td>81</td>
</tr>
<tr>
<td>best practice xiv–xv</td>
<td>129–32</td>
</tr>
<tr>
<td>'big data' 75, 76, 77, 83–7</td>
<td></td>
</tr>
<tr>
<td>biotechnology ventures</td>
<td>43–8</td>
</tr>
<tr>
<td>Birkenshaw, J. xiv</td>
<td></td>
</tr>
<tr>
<td>Bonte, Angelique 11, 12</td>
<td></td>
</tr>
<tr>
<td>bootstrapping 85, 102</td>
<td></td>
</tr>
<tr>
<td>bottom-up innovation</td>
<td>78</td>
</tr>
<tr>
<td>Braam, Hugo 95–6, 97, 98</td>
<td></td>
</tr>
<tr>
<td>Brabant Development Agency (BOM) 81</td>
<td></td>
</tr>
<tr>
<td>brainstorming 15, 78, 88–9, 127</td>
<td></td>
</tr>
<tr>
<td>branding 96, 97, 108, 110–11, 114, 115, 130</td>
<td></td>
</tr>
<tr>
<td>Brinkman, Thomas 70–73</td>
<td></td>
</tr>
<tr>
<td>budgets 6–7, 24, 32, 39, 64, 69, 73, 75, 78, 86, 90, 115, 120, 232</td>
<td></td>
</tr>
<tr>
<td>Buenen, Jan-Kees 83–7</td>
<td></td>
</tr>
<tr>
<td>bureaucracy xiv, xv–xvi, xviii, 125, 127, 128, 131</td>
<td></td>
</tr>
<tr>
<td>business cases 7–10, 25, 44, 73, 88–9, 112, 131</td>
<td></td>
</tr>
<tr>
<td>business models 4, 36, 45–6, 57–8, 63, 68, 73–4, 89, 119, 124</td>
<td></td>
</tr>
<tr>
<td>Campbell, A. xiv</td>
<td></td>
</tr>
<tr>
<td>Canon 52–3, 54</td>
<td></td>
</tr>
<tr>
<td>impact of Document Services Valley 63–5</td>
<td></td>
</tr>
<tr>
<td>ChusineZ 120</td>
<td></td>
</tr>
<tr>
<td>advancing insights 19–20</td>
<td></td>
</tr>
<tr>
<td>model 8, 10, 11, 12–15, 122</td>
<td></td>
</tr>
<tr>
<td>and parent 2–4</td>
<td></td>
</tr>
<tr>
<td>parent company relationship</td>
<td>17–19, 127</td>
</tr>
<tr>
<td>portfolio 15–16, 124</td>
<td></td>
</tr>
<tr>
<td>profit model 20–21</td>
<td></td>
</tr>
<tr>
<td>strategic aims and incremental value change 13</td>
<td></td>
</tr>
<tr>
<td>structure 4</td>
<td></td>
</tr>
<tr>
<td>team composition 16–17, 125, 126</td>
<td></td>
</tr>
<tr>
<td>vision 4–6</td>
<td></td>
</tr>
<tr>
<td>venture development over time</td>
<td>16</td>
</tr>
<tr>
<td>venture process 6–7</td>
<td></td>
</tr>
<tr>
<td>venture stages</td>
<td>13</td>
</tr>
<tr>
<td>venture type identification</td>
<td>19</td>
</tr>
<tr>
<td>chemical industry 23–4, 26–8</td>
<td></td>
</tr>
<tr>
<td>emerging themes 35–6</td>
<td></td>
</tr>
<tr>
<td>Chesbrough, H. 13</td>
<td></td>
</tr>
<tr>
<td>coaching 61, 64, 81, 94, 96, 126, 127</td>
<td></td>
</tr>
<tr>
<td>commercial agreements 47</td>
<td></td>
</tr>
<tr>
<td>community banking</td>
<td>77</td>
</tr>
<tr>
<td>competition 21, 32, 66, 83–4, 88, 94, 98, 106</td>
<td></td>
</tr>
<tr>
<td>concept description xvi</td>
<td>62</td>
</tr>
<tr>
<td>concept testing xvi</td>
<td>26, 57, 59, 61, 62, 73–5, 86, 89–90, 109–12, 122</td>
</tr>
<tr>
<td>Consumer 2020 76, 77</td>
<td></td>
</tr>
<tr>
<td>continuous development 13, 122</td>
<td></td>
</tr>
<tr>
<td>convertible loans 100</td>
<td></td>
</tr>
<tr>
<td>Coombs, John 42, 44, 45–6, 47, 48–9, 50–51, 122</td>
<td></td>
</tr>
</tbody>
</table>
Index

cooperative banking 69–70, 75, 78
cooperative venturing 6, 24, 120, 125, 126
core business xviii, 42, 43, 73, 127, 128, 129
core innovation xvii
crashed ventures 19
creativity xv, xvii, 53, 91, 118, 122, 131
critical mass 13, 65
crowd-funding 75, 132
culture 18, 23–4, 65, 68, 72, 109–10, 114, 128, 130
customer relations 74, 79
CZ Zorgverzekeringen 2–4
Health Care Innovation Department 6
and subsidiary 2–4
structure 3
venture organization relationship 17–19
de Groot, Joep 2, 3, 4, 6–7, 8, 9–11, 12, 15, 16, 17, 18, 19, 20, 21
de Jong, Bart 81, 82–3, 87, 88–90, 91, 92, 124
differentiation 109–12, 115
Document Services Valley (DSV)
development funnel 60
formation 54–5
future strategy 65–6
impact on Canon 63–5, 128
model 59–61
portfolio 61–3, 124
Programme for Acceleration of (Document) Services Innovation (PADSI) xvi, 56, 62, 66
structure and organization 55–6
team composition 65
Dooijes, Michael 68–9, 74, 75, 77–8, 79
Dow Jones Sustainability Indices (DJSI) 23
drug approval process 45–6
Dutch BV 64
e-health ventures 7–12
e-invoicing 77
Eijsink 70–71
Eindhoven University of Technology (TU/e) 57
structure 82
Eindhoven University of Technology
InnovationLab 120
birth 81–2
future 92
model 87–90, 122
portfolio 90–91, 124
spin-offs 82–3
team composition 91
venture relationship 87, 92, 127–8
energy technology 35–6
entrepreneurial culture 72, 130
entrepreneurial spirit xiv, xvi, 38, 78, 125, 126, 129, 130
entrepreneurship 17, 23, 56, 65, 72, 73, 77, 83, 94, 95, 120–21, 132
‘escalation of commitment’ 33, 121–2, 131
EuMediaNet 63
European Horizon 2020 programme 36, 38
exit 13, 46–8, 51, 60, 66, 90, 118
experiences, capturing 132
experimentation 73, 81, 109–12, 114, 117, 118, 122, 123
Exser 54, 64
external venturing xiv, 60, 70, 120–21, 126
‘fail often, fail early, fail cheap’ principle 131
failure
learning from 27–8, 130
non-punishment of 131
‘false negatives’ 122–3
finance
AkzoNobel New Ventures 26, 27, 28, 29, 30, 31–2
CbusineZ 6–7
Document Services Valley 56, 58, 63–4, 65, 66
Eindhoven University of Technology
InnovationLab 83, 89–90
NRC Handelsblad 109
Rabobank 71, 72, 75, 77
SanomaVentures 97, 99, 100, 101, 102, 103
Unilever Ventures 45, 46, 49
financial buyers 46
financial services industry 68–73
Het Financieel Dagblad 109
FinTech industry 68, 75, 76
Five Park Lane 86
flatliner ventures 19
Fleming Family & Partners 44–5
flexibility xv–xvi, xviii, 19, 34, 35, 92, 95, 102, 115, 127
focus groups 109
Food and Drug Administration (FDA), US 45–6
fraud investigations 86–7
freedom xv–xvi, xviii, 19, 38, 88, 117, 121, 127, 128
Index

Netherlands
health care 2, 4–6
increase in chronic diseases 4, 5
network visualization 84
networks/networking 55, 56–7, 58, 61–2, 63, 78, 84, 87, 92, 94, 97, 103, 130
new combinations xv
newspaper industry 106–16
North Brabant Development Agency 62

‘not invented here’ syndrome xv, 15, 40, 127

Nijenhuis, Hans 111, 112, 113–14, 115–16, 119

NRC Handelsblad
from experimentation to innovation 109–12
future 119
model 117–18, 123
need for innovation 108–9
and PCM Uitgevers 106–8
portfolio 118
team composition 118, 126
venture relationship 118, 127

nrc·next 110–13, 120–21, 127
editorial board 113–14
internal changes 116
parent company relationship 118
run-up and launch 114–16

Océ 52–3, 120, 122, 126
innovation 53–4
open innovation 56
Osterwalder, A. 74

parent organization connections
AkzoNobel New Ventures 38–40
CbusineZ 17–19
Document Services Valley 63–5
Eindhoven University of Technology InnovationLab 92
NRC Handelsblad 118–19
Rabobank 78–9
SanomaVentures 101–2
Unilever Ventures 50
participation agreements 8, 18
partnerships 3, 4, 6, 7–12, 18, 20, 27, 64, 65, 72, 85, 120, 125, 126
benefiting from 131
Patent Cooperation Treaty (PCT) 89
patents 44–5, 47, 53, 83, 87–8, 89, 95
PCM Uitgevers 106–10
structure 107

performance rewards 49
best practice 131
personalized health and fitness 95–8
Pigneur, Y. 74
pilot process 26, 27, 28, 57, 59, 61, 109
pitching 59, 61, 70, 75, 98, 99, 101
pockets of innovation 69–70, 78
portfolios xvii
AkzoNobel New Ventures 34–6
best practice 130
CbusineZ 15–16
discussion 123–5
Document Services Valley 61–3
Eindhoven University of Technology InnovationLab 90–91
NRC Handelsblad 118
Rabobank 75–7
SanomaVentures 100–101
Unilever Ventures 49
pre-seed funding 83
pricing 107–8, 109, 118
printing industry 53–4
process technology 35
professionalization 3, 7, 13, 18, 59, 83, 97
profit-sharing agreements 7
proof-of-concept loans 92
prototypes 83, 89–90, 96, 97
Psy Health Direct 4, 126
business case 7–10
evolution 10–12, 20–21
Pulp & Paper Chemicals 26–7
lessons from failure 27–8

QBengo 56–8
quality 16, 17, 50, 99, 108–9, 112, 113, 124

Rabobank 68
venture organization relationship 78–9
Rabobank Strategy and Innovation Department
model 73–5
new dynamic 79
parent company relationship 78–9
portfolio 75–7
structure and organization 68–70
team composition 77–8
radical innovation xv, 68, 69
research and development (R&D) 24, 31, 44, 50, 53, 90, 92, 120, 127, 130
revenues 7, 26, 28, 30, 32, 39, 46, 58, 63, 74, 99, 100, 115
projections 29, 30
revolving funds 66, 92, 103
Ries, Eric 122, 123
risk 7, 18, 24, 25, 28, 37, 63, 91, 100, 109, 110, 125
risk management xvii, xviii, 46, 48–9, 58, 68, 123, 124, 128
sales and marketing 10, 11, 14, 20–21, 44, 45–6, 49, 55, 57, 58, 72, 79, 84, 97, 98, 106, 111, 123
Sanoma 94
venture company relationship 101–2
SanomaVentures 120
future 102–4
innovation 94–5
investment process 99
model 98–100
parent company relationship 101–2, 127
portfolio 100–101, 123–4
strategic goals 95
team composition 102, 126
SBS Broadcasting Group 94
Schumpeter, J.A. xv
scientific research commercialization 81–7
secondment 55
seed funding 85–6, 96
segmentation 109–12
self-management 8, 16, 17, 96, 124
shareholding 31–2, 66, 71, 90, 100, 102
majority 71, 102, 103
minority 97, 100, 126
Shell 72, 79
Siemens Nixdorf 53
Sierkstra, Laurens 43–5, 46, 47, 48, 50
Silicon Valley 85, 104
skills xiv, xvii, 17, 37, 51, 65, 78, 85, 91, 97, 117, 126
'Skype banking' 77
slow growth ventures 19
smart materials 35
smart technology 70–73, 76, 77
smartphone applications 56–8
speed, importance of 131
spin-offs 82–3, 87, 89, 90
distinction with start-ups 82–3
spin-outs 32, 43–6, 49–50
sale of 46–8
stage-gate models xvi, 16, 19, 25, 33–4, 40, 62, 117–18
best practice 131
Eindhoven University of Technology InnovationLab 87–90
SanomaVentures 98–100
weaknesses 48–9, 121–2
stagnant ventures 19
start-ups, distinction with spin-offs 82–3
strategic alignment 49, 58, 78–9, 124, 130
strategic buyers 46–7
strategic entrepreneurship 120–21
strategic focus 35, 124, 125
strategic objectives 2–3, 20, 85, 87, 90–91, 92, 103, 117, 121, 124, 127
strategic value 3, 7, 9, 18, 20, 100
strategic vision xvii, xviii, 2, 4, 29, 32, 34, 76, 84–5, 122, 123
success rates xiv
supply chain 25, 29, 71, 77
support services 3–4, 16, 18–19, 27, 40, 49, 55, 56, 88, 69–70, 71, 81, 82, 83, 91, 96–7, 99
sustainability 4–5, 23, 49, 83, 120–21
synergies xvii, 130, 132
Synerscope 83–7
relationship with TU/e InnovationLab 87, 92, 187–8
target markets 4, 8, 9, 53–4, 58, 71, 75, 96–7, 108–13, 120–21
targets 51, 79, 97, 99, 103, 115, 117, 122
team composition
AkzoNobel New Ventures 36–8
best practice 129, 132
CbusineZ 16–17
discussion 125–6
Document Services Valley 65
Eindhoven University of Technology InnovationLab 91
NRC Handelsblad 118
Rabobank 77–8
SanomaVentures 102
Unilever Ventures 49–50
team size 132
technical functionality 28
Teckle 69
timing, importance of 28
<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>top management commitment</td>
<td>65, 66, 92, 126, 130</td>
</tr>
<tr>
<td>transformational innovation</td>
<td>xvii, 122</td>
</tr>
<tr>
<td>Tuff, G.</td>
<td>xvi, 122</td>
</tr>
<tr>
<td>Unilever</td>
<td>41–2</td>
</tr>
<tr>
<td>structure</td>
<td>42</td>
</tr>
<tr>
<td>venture organization relationship</td>
<td>50</td>
</tr>
<tr>
<td>Unilever Ventures</td>
<td></td>
</tr>
<tr>
<td>breeding success</td>
<td>50–51</td>
</tr>
<tr>
<td>formation</td>
<td>42</td>
</tr>
<tr>
<td>model</td>
<td>48–9, 122</td>
</tr>
<tr>
<td>parent company relationship</td>
<td>50, 128</td>
</tr>
<tr>
<td>portfolio</td>
<td>49</td>
</tr>
<tr>
<td>structure</td>
<td>42</td>
</tr>
<tr>
<td>team composition</td>
<td>49–50, 51</td>
</tr>
<tr>
<td>USA, venture capital</td>
<td>xiv</td>
</tr>
<tr>
<td>vaccine manufacture</td>
<td>43</td>
</tr>
<tr>
<td>value added</td>
<td>18, 26, 27, 38, 56, 58, 65, 76, 90, 95, 101, 111–12, 119</td>
</tr>
<tr>
<td>van der Grinten, Lodewijk</td>
<td>53</td>
</tr>
<tr>
<td>van der Heide, Remon</td>
<td>56–8</td>
</tr>
<tr>
<td>van Es, Gijsbert</td>
<td>110</td>
</tr>
<tr>
<td>Van Gemeren, Ingbeorg</td>
<td>44, 45, 48</td>
</tr>
<tr>
<td>venture capital/capitalists</td>
<td>xiv, 31, 42, 48–9, 51, 64, 89–90, 103, 110, 128</td>
</tr>
<tr>
<td>Verschaeren, Jan</td>
<td>52–3, 64, 65, 66</td>
</tr>
<tr>
<td>VirtuaGym</td>
<td>95–8</td>
</tr>
<tr>
<td>VNU</td>
<td>94</td>
</tr>
<tr>
<td>De Volkskrant</td>
<td>108</td>
</tr>
<tr>
<td>Vollaard, Harrie</td>
<td>68, 69–70, 73, 75, 78</td>
</tr>
<tr>
<td>Zeitler, Mike</td>
<td>24, 39</td>
</tr>
</tbody>
</table>